(+)-Morphinan N-Oxide Synthesis via Direct Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for processes to synthesize (+)-morphinanium N-oxides, which are potent inhibitors of vascular endothelial growth factor (VEGF) independent of stereochemistry, as they do not interact with opiate receptors, offering potential as improved VEGF inhibitors for tumor treatment and macular degeneration.
Innovation Solution
The synthesis of (+)-morphinanium N-oxides is achieved through the direct N-oxidation of tertiary amines from corresponding (+)-morphinan compounds using an oxidizing agent, such as hydrogen peroxide, to produce quaternary amine compounds with specific structural formulas (II) and (IV), and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If (+)-morphinan compounds are used as VEGF inhibitors, then VEGF inhibition activity is achieved, but interaction with opiate receptors occurs causing unwanted side effects
Solution Approach 1:
The patent applies parameter changes by oxidizing the nitrogen atom in the morphinan structure to form an N-oxide. This chemical modification changes the electrostatic and steric parameters of the molecule, allowing it to inhibit VEGF while preventing interaction with opiate receptors. The N-oxide functional group fundamentally alters the molecule's properties compared to the parent tertiary amine structure.
2Reliability
If (-)-morphinan quaternary compounds are used for VEGF inhibition, then potent VEGF inhibitory activity is achieved, but synthesis complexity increases due to stereochemical requirements
Solution Approach 1:
The patent inverts the conventional approach by using (+)-morphinan compounds instead of (-)-morphinan compounds. Since VEGF inhibitory activity appears independent of stereochemistry, this inversion simplifies synthesis by avoiding the need to produce and separate enantiomers, while still achieving the desired biological effect.
Solution Approach 2:
The patent extracts the essential VEGF-inhibiting structural features from the complex stereochemical requirements. By demonstrating that (+)-morphinan N-oxides achieve VEGF inhibition without requiring specific stereocenters, the invention extracts the core functional elements while eliminating unnecessary stereochemical complexity.
3Reliability
If N-oxides of morphinans are synthesized, then improved VEGF inhibition without opiate interaction is achieved, but synthesis process complexity increases
Solution Approach 1:
The patent applies parameter changes by oxidizing the nitrogen atom in the morphinan structure to form an N-oxide. This chemical modification changes the electrostatic and steric parameters of the molecule, allowing it to inhibit VEGF while preventing interaction with opiate receptors. The N-oxide functional group fundamentally alters the molecule's properties compared to the parent tertiary amine structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively produces (+)-morphinanium N-oxides that can serve as effective VEGF inhibitors, providing a pharmaceutical solution for treating tumors and macular degeneration without opiate receptor interaction.
Implementation Method 1
The synthesis of (+)-morphinanium N-oxides is achieved through the direct N-oxidation of tertiary amines from corresponding (+)-morphinan compounds using an oxidizing agent, such as hydrogen peroxide
Data Source
AI summary
The present invention provides (+)-morphinanium N-oxide compounds or pharmaceutically acceptable salts thereof. The invention also provides processes for producing (+)-morphinanium N-oxides or pharmaceutically acceptable salts thereof from the corresponding tertiary N-substituted (+)-morphinan compound or pharmaceutically acceptable salt thereof.